Compare · DXCM vs IRMD
DXCM vs IRMD
Side-by-side comparison of DexCom Inc. (DXCM) and iRadimed Corporation (IRMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IRMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 29.0x IRMD ($1.14B).
- DXCM has hit the wire 6 times in the past 4 weeks while IRMD has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 2 for IRMD).
- Company
- DexCom Inc.
- iRadimed Corporation
- Price
- -
- -
- Market cap
- $33.10B
- $1.14B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2014
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 2
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
iRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest IRMD
- Director Kiani Joe E converted options into 698 shares (SEC Form 4)
- IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
- Needham initiated coverage on iRadimed
- Director Allen Monty K sold $122,622 worth of shares (1,419 units at $86.41), decreasing direct ownership by 7% to 19,581 units (SEC Form 4)
- SEC Form 144 filed by iRadimed Corporation
- Amendment: iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Other Events
- SEC Form 10-Q filed by iRadimed Corporation
- iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
- IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026